TM-38837

Uses your system voice; voice and rate in settings.

Q7670627Snapshot

≈ 2 min read

Names in other languages

  • EnglishTM-38837
  • shTM-38837
  • СрпскиTM-38837

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

TM-38837 is a small molecule inverse agonist/antagonist of the CB 1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials. TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB 1 receptor antagonists such as rimonabant. The structure of TM-38837 has been erronously referred to in the past as compound 8 in reference but is now known from a more recent reference.

TM-38837 is a small molecule inverse agonist/antagonist of the CB 1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials. TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB 1 receptor antagonists such as rimonabant. The structure of TM-38837 has been erronously referred to in the past as compound 8 in reference but is now known from a more recent reference.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1371351332 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.